Latest Europe News

Provaris Energy has made significant strides in hydrogen and liquid carbon dioxide storage technologies, reinforcing key partnerships and securing funding to meet critical 2026 milestones.

Seafarms Group has completed the acquisition of Project Sea Dragon's assets, clearing legal hurdles and advancing its prawn farming operations while actively pursuing new funding to support growth.

Elementos Limited advances its Oropesa and Cleveland tin projects with a strategic smelter acquisition and a $9.1 million capital raise, positioning itself strongly amid rising tin prices.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Unith Ltd reports a 17% rise in quarterly cash receipts alongside strategic funding and new technology launches, signalling momentum in its AI-driven digital human platform.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

Impact Minerals reports significant advancements in its High Purity Alumina projects, a strategic collaboration with US battery innovator C4V, and renewed exploration activities in NSW’s Broken Hill region.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Kuniko Limited has advanced exploration at its Commonwealth Gold–Silver Project in NSW, completing key surveys and securing approvals ahead of a planned diamond drilling campaign in February 2026. Meanwhile, its Nordic battery metals portfolio remains strategically positioned for future development.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.